In 2017, China became the world's second-largest national pharmaceutical market, due to its aging population and rising medical needs. In its ongoing commitment to adapt to emerging trends in the pharmaceutical industry, Eurofins Central Laboratory, a member of Eurofins BioPharma Services, has expanded its facility in Shanghai, China.
What is Brexit?
The deadline for the United Kingdom to withdraw from the European Union, known as Brexit, is quickly approaching. The formal date will be March 29, 2019. In June 2016, Britain held a national referendum on their European Union membership, and having to choose between remain and leave, the British voted to leave by 52%. After 18 months of negotiating a divorce plan on trade, security and migration matters with European Union, the deal was rejected by the British Parliament just 10 weeks before Britain is scheduled to leave the EU.
Today, at all four of our wholly-owned central laboratory testing facilities (United States, Netherlands, China, and Singapore), we at Eurofins Central Laboratory, a division of Eurofins BioPharma Services, wear red with the American Heart Association to aide in uniting the world from continent to continent in effort of bringing awareness to our friends, families, and colleagues suffering from cardiovascular-related diseases (CVD). Diseases under this remit include, but are not limited to, defects at birth, heart rhythm complications, and abnormal blood vessel conditions.
On January 27th, Eurofins Central Laboratory recognizes World Leprosy Day with the World Health Organization (WHO). Also known as Hansen’s disease, Leprosy is a chronic infectious disease caused by Mycobacterium Leprae. This disease affects the skin, peripheral nerves, mucus membranes of the upper respiratory tract, and eyes. Individuals affected will experience sensory loss in these affected areas as well as damaged thickened nerves.
Today we at Eurofins Central Laboratory recognize a rare neurological disorder known as Moebius Syndrome.
While we have numerous symptomatic treatments today, there is still no cure for neurodegenerative diseases such as Parkinson’s and Alzheimer’s. There are more than 600 neurodegenerative diseases alone that affect the brain, spine, and peripheral nervous system. While diseases like Parkinson’s affect motor functions, Alzheimer’s is a progressive disease that destroys memory and other mental functions.
Celebrating Thirty Years of Good Laboratory Practice
The GLP (Good Laboratory Practice) Testing Facility of Eurofins Central Laboratory in Breda, The Netherlands has been accredited for OECD GLP for over 30 years. It all started at the BCO Centre for Research (B for Bergschot 71, the street address ever since) with the first inspection by the Dutch Health Care Inspectorate in June 1988. Over the years, BCO underwent several transformations and evolved into becoming one of the Eurofins Central Laboratory facilities, keeping the GLP Test Facility embedded in the Breda Clinical Laboratory.
Throughout the month, Eurofins Central Laboratory, a member of Eurofins BioPharma Services, stands with the American Cancer Society to recognize January as Cervical Cancer Awareness Month. According to the World Health Organization (WHO):